首页 > 最新文献

Case Reports in Hematology最新文献

英文 中文
Refractory Immune Thrombocytopenic Purpura with Abdominal Splenosis: A Complex Case. 难治性免疫性血小板减少性紫癜合并腹部脾肿大:一例复杂病例。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/9714457
Joseph F Mort, Danh T Tran, Sean C Dougherty, Robert Zielinski, Michael D Williams, Kelly M Davidson

Immune thrombocytopenia (ITP) is an acquired thrombocytopenia resulting from immune-mediated platelet destruction via antiplatelet antibodies and T cells. Medical management of ITP includes corticosteroids and multiple other adjunct therapies, with splenectomy generally being reserved for severe, refractory cases. In this clinical case report, we describe the evaluation of a 35-year-old male with a history of prior traumatic splenic injury who presented to the emergency department endorsing easy bruising and a petechial rash, ultimately found to have severe thrombocytopenia. The patient was diagnosed with primary ITP that proved to be refractory to a number of first- and second-line medical therapies. His course was complicated by the presence of abdominal splenosis discovered at the time of planned splenectomy and intra-abdominal hemorrhage requiring splenic artery embolization thereafter. To our knowledge, this is one of few published cases of ITP complicated by abdominal splenosis, highlighting the need to consider splenosis and the presence of accessory splenic tissue in cases of refractory ITP.

免疫性血小板减少症(ITP)是一种获得性血小板减少症,由抗血小板抗体和T细胞免疫介导的血小板破坏引起。ITP的医疗管理包括皮质类固醇和多种其他辅助治疗,脾切除术通常用于严重的难治性病例。在这个临床病例报告中,我们描述了一名35岁男性的评估,他之前有外伤性脾损伤的历史,他到急诊科证实容易瘀伤和点疹,最终发现有严重的血小板减少症。该患者被诊断为原发性ITP,经证实对一些一线和二线药物治疗是难治的。他的病程因计划行脾切除术时发现腹部脾肿大和随后需要脾动脉栓塞术的腹内出血而变得复杂。据我们所知,这是少有的ITP合并腹部脾肿大的病例之一,强调在难治性ITP病例中需要考虑脾肿大和脾附属组织的存在。
{"title":"Refractory Immune Thrombocytopenic Purpura with Abdominal Splenosis: A Complex Case.","authors":"Joseph F Mort,&nbsp;Danh T Tran,&nbsp;Sean C Dougherty,&nbsp;Robert Zielinski,&nbsp;Michael D Williams,&nbsp;Kelly M Davidson","doi":"10.1155/2023/9714457","DOIUrl":"https://doi.org/10.1155/2023/9714457","url":null,"abstract":"<p><p>Immune thrombocytopenia (ITP) is an acquired thrombocytopenia resulting from immune-mediated platelet destruction via antiplatelet antibodies and T cells. Medical management of ITP includes corticosteroids and multiple other adjunct therapies, with splenectomy generally being reserved for severe, refractory cases. In this clinical case report, we describe the evaluation of a 35-year-old male with a history of prior traumatic splenic injury who presented to the emergency department endorsing easy bruising and a petechial rash, ultimately found to have severe thrombocytopenia. The patient was diagnosed with primary ITP that proved to be refractory to a number of first- and second-line medical therapies. His course was complicated by the presence of abdominal splenosis discovered at the time of planned splenectomy and intra-abdominal hemorrhage requiring splenic artery embolization thereafter. To our knowledge, this is one of few published cases of ITP complicated by abdominal splenosis, highlighting the need to consider splenosis and the presence of accessory splenic tissue in cases of refractory ITP.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"9714457"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9729622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pyruvate Kinase Deficiency Causing Priapism. 丙酮酸激酶缺乏引起阴茎勃起障碍。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/6503311
Vinay Hanyalu Shankar, Bharadwaj Adithya-Sateesh, Nicole Gousy, Girma Ayele, Freyr Petursson, Rediet Atalay, Miriam Michael

Pyruvate kinase deficiency (PKD) is an autosomal recessive defect of the enzyme pyruvate kinase (PK) which is involved in catalyzing a reaction that produces ATP in the glycolytic pathway. It is the most common defect of the glycolytic pathway associated with congenital anemia. Patients usually present with signs of chronic hemolytic anemia such as hyperbilirubinemia, splenomegaly, reticulocytosis, and gallstones; the presentation can vary by age. Diagnosis is usually made by demonstration of decreased PK enzymatic activity in a spectrophotometric assay and on the detection of mutations in the PK-LR gene. Management strategies vary from full splenectomies to hematopoietic stem cell transplants with gene therapies with transfusions and administration of PK-activators coming in between. Thromboembolic complications do occur in patients with splenectomy, but there are not much data regarding this for patients with PKD. We present a case of a patient with PKD who demonstrated priapism to be a thromboembolic complication. This differs greatly as priapism has been frequently reported in patients with other chronic hemoglobinopathies such as sickle cell disease, thalassemia, and G6PD with and without splenectomy. While it is still unclear how splenectomies can result in thrombotic events in PKD, there does appear to be a correlation between splenectomies with resultant thrombocytosis with increased platelet adhesion.

丙酮酸激酶缺乏症(PKD)是丙酮酸激酶(PK)酶的常染色体隐性缺陷,它参与催化糖酵解途径中产生ATP的反应。它是与先天性贫血相关的糖酵解途径最常见的缺陷。患者通常有慢性溶血性贫血的症状,如高胆红素血症、脾肿大、网状红细胞增多症和胆结石;表现会因年龄而异。诊断通常是通过分光光度法测定PK酶活性降低和检测PK- lr基因突变来进行的。治疗策略各不相同,从全脾切除到造血干细胞移植,再加上基因治疗和输注pk -激活剂。脾切除术患者确实会发生血栓栓塞并发症,但关于PKD患者的相关数据并不多。我们提出一个病例的病人PKD谁证明阴茎勃起是一个血栓栓塞并发症。这与其他慢性血红蛋白病(如镰状细胞病、地中海贫血和G6PD)伴脾切除或不伴脾切除的患者经常报道的勃起功能障碍有很大的不同。虽然目前尚不清楚脾切除术如何导致PKD的血栓事件,但脾切除术与由此产生的血小板增多和血小板粘连增加之间似乎存在相关性。
{"title":"Pyruvate Kinase Deficiency Causing Priapism.","authors":"Vinay Hanyalu Shankar,&nbsp;Bharadwaj Adithya-Sateesh,&nbsp;Nicole Gousy,&nbsp;Girma Ayele,&nbsp;Freyr Petursson,&nbsp;Rediet Atalay,&nbsp;Miriam Michael","doi":"10.1155/2023/6503311","DOIUrl":"https://doi.org/10.1155/2023/6503311","url":null,"abstract":"<p><p>Pyruvate kinase deficiency (PKD) is an autosomal recessive defect of the enzyme pyruvate kinase (PK) which is involved in catalyzing a reaction that produces ATP in the glycolytic pathway. It is the most common defect of the glycolytic pathway associated with congenital anemia. Patients usually present with signs of chronic hemolytic anemia such as hyperbilirubinemia, splenomegaly, reticulocytosis, and gallstones; the presentation can vary by age. Diagnosis is usually made by demonstration of decreased PK enzymatic activity in a spectrophotometric assay and on the detection of mutations in the PK-LR gene. Management strategies vary from full splenectomies to hematopoietic stem cell transplants with gene therapies with transfusions and administration of PK-activators coming in between. Thromboembolic complications do occur in patients with splenectomy, but there are not much data regarding this for patients with PKD. We present a case of a patient with PKD who demonstrated priapism to be a thromboembolic complication. This differs greatly as priapism has been frequently reported in patients with other chronic hemoglobinopathies such as sickle cell disease, thalassemia, and G6PD with and without splenectomy. While it is still unclear how splenectomies can result in thrombotic events in PKD, there does appear to be a correlation between splenectomies with resultant thrombocytosis with increased platelet adhesion.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"6503311"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9486016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia. 多系淋巴母细胞淋巴瘤是混合表型急性白血病的初始表现。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/3628712
Mako Ikeda, Wataru Nakahara, Mizuki Asako, Yuka Umeki, Yoshiki Matsuoka, Takuya Terakawa, Hitomi Matsunaga, Yuki Iwasa, Riko Saito, Yuki Iwama, Takahiro Matsui, Kazumasa Oka, Shuji Ueda

Mixed phenotype acute leukemia (MPAL) is characterized by leukemic blasts that express markers of multiple lineages. Compared with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), MPAL is considered to have a poor treatment outcome. We report a case of MPAL T/myeloid not otherwise specified that was initially presented as multilineage lymphoblastic lymphoma and subsequently developed into leukemic MPAL. An acute lymphoblastic leukemia-based treatment regimen was ineffective, but azacitidine and venetoclax therapy resulted in hematological complete remission. Our case suggests that multilineage lymphoblastic lymphoma should be considered to be the same disease as MPAL, albeit with different clinical presentations. Optimal treatment for MPAL has not been established yet, but azacitidine and venetoclax therapy may be a potential approach.

混合表型急性白血病(MPAL)的特点是白血病母细胞表达多个谱系的标记。与急性髓性白血病(AML)和急性淋巴细胞白血病(ALL)相比,MPAL被认为具有较差的治疗效果。我们报告一例MPAL的T/髓系未另有说明,最初表现为多系淋巴母细胞淋巴瘤,随后发展为白血病MPAL。急性淋巴细胞白血病为基础的治疗方案是无效的,但阿扎胞苷和venetoclax治疗导致血液学完全缓解。我们的病例提示,尽管临床表现不同,但多系淋巴母细胞淋巴瘤应被视为与MPAL相同的疾病。MPAL的最佳治疗方法尚未确定,但阿扎胞苷和venetoclax治疗可能是一种潜在的方法。
{"title":"Multilineage Lymphoblastic Lymphoma as an Initial Presentation of Mixed Phenotype Acute Leukemia.","authors":"Mako Ikeda,&nbsp;Wataru Nakahara,&nbsp;Mizuki Asako,&nbsp;Yuka Umeki,&nbsp;Yoshiki Matsuoka,&nbsp;Takuya Terakawa,&nbsp;Hitomi Matsunaga,&nbsp;Yuki Iwasa,&nbsp;Riko Saito,&nbsp;Yuki Iwama,&nbsp;Takahiro Matsui,&nbsp;Kazumasa Oka,&nbsp;Shuji Ueda","doi":"10.1155/2023/3628712","DOIUrl":"https://doi.org/10.1155/2023/3628712","url":null,"abstract":"<p><p>Mixed phenotype acute leukemia (MPAL) is characterized by leukemic blasts that express markers of multiple lineages. Compared with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), MPAL is considered to have a poor treatment outcome. We report a case of MPAL T/myeloid not otherwise specified that was initially presented as multilineage lymphoblastic lymphoma and subsequently developed into leukemic MPAL. An acute lymphoblastic leukemia-based treatment regimen was ineffective, but azacitidine and venetoclax therapy resulted in hematological complete remission. Our case suggests that multilineage lymphoblastic lymphoma should be considered to be the same disease as MPAL, albeit with different clinical presentations. Optimal treatment for MPAL has not been established yet, but azacitidine and venetoclax therapy may be a potential approach.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"3628712"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10849527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
WHIM Syndrome: First Reported Case in a Patient of African Ancestry. WHIM综合征:首例非洲血统患者报告病例。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/3888680
Jinal Gandhi, Michelle H Lee, Lynsie Adams, Tara Shrout Allen, Julie Li, Camille Vanessa Edwards

Background: Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare, primary immunodeficiency syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and characteristic bone marrow features of myelokathexis. The pathophysiology of WHIM syndrome is due to an autosomal dominant gain of function mutation in the CXCR4 chemokine receptor resulting in increased activity that impairs neutrophil migration from the bone marrow into the peripheral blood. This results in bone marrow distinctively crowded with mature neutrophils whose balance is shifted towards cellular senescence developing these characteristic, apoptotic nuclei termed myelokathexis. Despite the resultant severe neutropenia, the clinical syndrome is often mild and accompanied by a variety of associated abnormalities that we are just beginning to understand. Case Report. Diagnosis of WHIM syndrome is incredibly difficult due to phenotypic heterogeneity. To date, there are only about 105 documented cases in the scientific literature. Here, we describe the first case of WHIM syndrome documented in a patient of African ancestry. The patient in question was diagnosed at the age of 29 after a comprehensive work-up for incidental neutropenia discovered at a primary care appointment at our center in the United States. In hindsight, the patient had a history of recurrent infections, bronchiectasis, hearing loss, and VSD repair that could not be previously explained.

Conclusions: Despite the challenge of timely diagnosis and the wide spectrum of clinical features that we are still discovering, WHIM syndrome tends to be a milder immunodeficiency that is highly manageable. As presented in this case, most patients respond well to G-CSF injections and newer treatments such as small-molecule CXCR4 antagonists.

背景:疣、低γ -球蛋白血症、感染和骨髓增生综合征(WHIM)是一种罕见的原发性免疫缺陷综合征,其特征为疣、低γ -球蛋白血症、免疫缺陷和骨髓增生的特征性特征。WHIM综合征的病理生理是由于CXCR4趋化因子受体的常染色体显性功能突变,导致活性增加,损害中性粒细胞从骨髓向外周血的迁移。这导致骨髓明显挤满成熟的中性粒细胞,其平衡向细胞衰老转移,形成这些特征,凋亡核称为骨髓增生。尽管结果是严重的中性粒细胞减少症,临床综合征往往是轻微的,并伴有各种相关的异常,我们才刚刚开始了解。病例报告。由于表型异质性,WHIM综合征的诊断非常困难。到目前为止,在科学文献中只有大约105个记录在案的病例。在这里,我们描述的第一个病例WHIM综合征记录在一个病人的非洲血统。患者在29岁时被诊断为偶然中性粒细胞减少症,在美国我们中心的一次初级保健预约中发现。事后看来,患者有反复感染、支气管扩张、听力损失和室间隔修复的病史,这些病史以前无法解释。结论:尽管及时诊断的挑战和广泛的临床特征,我们仍在发现,WHIM综合征往往是一种较轻的免疫缺陷,是高度可控的。正如本病例所述,大多数患者对G-CSF注射和小分子CXCR4拮抗剂等新疗法反应良好。
{"title":"WHIM Syndrome: First Reported Case in a Patient of African Ancestry.","authors":"Jinal Gandhi,&nbsp;Michelle H Lee,&nbsp;Lynsie Adams,&nbsp;Tara Shrout Allen,&nbsp;Julie Li,&nbsp;Camille Vanessa Edwards","doi":"10.1155/2023/3888680","DOIUrl":"https://doi.org/10.1155/2023/3888680","url":null,"abstract":"<p><strong>Background: </strong>Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare, primary immunodeficiency syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and characteristic bone marrow features of myelokathexis. The pathophysiology of WHIM syndrome is due to an autosomal dominant gain of function mutation in the CXCR4 chemokine receptor resulting in increased activity that impairs neutrophil migration from the bone marrow into the peripheral blood. This results in bone marrow distinctively crowded with mature neutrophils whose balance is shifted towards cellular senescence developing these characteristic, apoptotic nuclei termed myelokathexis. Despite the resultant severe neutropenia, the clinical syndrome is often mild and accompanied by a variety of associated abnormalities that we are just beginning to understand. <i>Case Report</i>. Diagnosis of WHIM syndrome is incredibly difficult due to phenotypic heterogeneity. To date, there are only about 105 documented cases in the scientific literature. Here, we describe the first case of WHIM syndrome documented in a patient of African ancestry. The patient in question was diagnosed at the age of 29 after a comprehensive work-up for incidental neutropenia discovered at a primary care appointment at our center in the United States. In hindsight, the patient had a history of recurrent infections, bronchiectasis, hearing loss, and VSD repair that could not be previously explained.</p><p><strong>Conclusions: </strong>Despite the challenge of timely diagnosis and the wide spectrum of clinical features that we are still discovering, WHIM syndrome tends to be a milder immunodeficiency that is highly manageable. As presented in this case, most patients respond well to G-CSF injections and newer treatments such as small-molecule CXCR4 antagonists.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"3888680"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10856156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Friend or Foe: Factor XII Deficiency Discovered Incidentally during Management of NSTEMI. 朋友还是敌人:在非stemi治疗过程中偶然发现的因子12缺乏。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/5926340
Patrick J Beck, John Benfield, Joshua Morales

Factor XII (FXII) deficiency is a rare coagulopathy that typically goes undiagnosed due to the lack of abnormal bleeding or thrombosis. However, the accompanying prolonged activated partial thromboplastin time (aPTT) can create difficulties with maintaining therapeutic anticoagulation in the setting of acute coronary syndrome (ACS). Here, we present the case of a 52-year-old man presenting with chest pain and diagnosed with an NSTEMI but also found with a prolonged baseline aPTT ultimately secondary to FXII deficiency. Here, we discuss the diagnostic work-up of an isolated prolonged aPTT to identify possible etiologies, such as FXII deficiency, and ultimately inform ACS management.

因子XII (FXII)缺乏症是一种罕见的凝血病,通常由于缺乏异常出血或血栓而无法诊断。然而,在急性冠状动脉综合征(ACS)的情况下,伴随的延长的活化部分凝血活素时间(aPTT)会给维持治疗性抗凝造成困难。在这里,我们报告了一名52岁男性的病例,其表现为胸痛,诊断为非stemi,但也发现基线aPTT延长,最终继发于FXII缺乏。在这里,我们讨论了一个孤立的延长aPTT的诊断工作,以确定可能的病因,如FXII缺乏,并最终告知ACS管理。
{"title":"Friend or Foe: Factor XII Deficiency Discovered Incidentally during Management of NSTEMI.","authors":"Patrick J Beck,&nbsp;John Benfield,&nbsp;Joshua Morales","doi":"10.1155/2023/5926340","DOIUrl":"https://doi.org/10.1155/2023/5926340","url":null,"abstract":"<p><p>Factor XII (FXII) deficiency is a rare coagulopathy that typically goes undiagnosed due to the lack of abnormal bleeding or thrombosis. However, the accompanying prolonged activated partial thromboplastin time (aPTT) can create difficulties with maintaining therapeutic anticoagulation in the setting of acute coronary syndrome (ACS). Here, we present the case of a 52-year-old man presenting with chest pain and diagnosed with an NSTEMI but also found with a prolonged baseline aPTT ultimately secondary to FXII deficiency. Here, we discuss the diagnostic work-up of an isolated prolonged aPTT to identify possible etiologies, such as FXII deficiency, and ultimately inform ACS management.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"5926340"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9810394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the Literature. 埃利希体病与噬血细胞相关的淋巴组织细胞增多症:病例系列和文献综述。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/5521274
Kassem Hammoud, Robert Fulmer, Megan Hamner, Wissam El Atrouni
Background Human monocytic ehrlichiosis (HME) is a potentially life-threatening tick-borne illness. HME-associated hemophagocytic lymphohistiocytosis (HLH) is a rare entity with a paucity of published literature regarding treatment and outcome. We present the clinical features, treatment, and outcomes of 4 patients at our institutions with HME-associated HLH. This review also summarizes the current literature regarding the presentation, treatment, and outcome of this infection-related HLH. Methods We searched the PubMed database for case reports and case series. All cases were diagnosed according to the HLH-04 criteria. Results Four cases of HME-associated HLH were included from our institutions. The literature review yielded 30 additional cases. About 41% of the cases were in the pediatric population; 59% were female; and all patients had fever, cytopenia, and elevated ferritin. Most patients were immunocompetent; all but one patient with available data were treated with doxycycline, and eight of the patients with available data received the HLH-94 treatment protocol. The mortality rate was 17.6%. Conclusions HME-associated HLH is a rare but serious syndrome with significant mortality. Early treatment with doxycycline is critical, but the role of immunosuppressive therapy is individualized.
背景:人单核细胞埃利希体病(HME)是一种潜在威胁生命的蜱传疾病。hme相关的噬血细胞淋巴组织细胞病(HLH)是一种罕见的实体,缺乏关于治疗和结果的已发表文献。我们介绍了在我们的机构中患有hme相关HLH的4例患者的临床特征、治疗和结果。这篇综述还总结了目前关于这种感染相关的HLH的表现、治疗和结果的文献。方法:检索PubMed数据库的病例报告和病例系列。所有病例均按照HLH-04标准诊断。结果:本院共纳入4例hme相关HLH病例。文献回顾发现了另外30例病例。大约41%的病例发生在儿科人群中;59%为女性;所有患者均有发热、细胞减少和铁蛋白升高。大多数患者具有免疫功能;除1例有可用数据的患者外,所有患者均接受强力霉素治疗,8例有可用数据的患者接受了HLH-94治疗方案。死亡率为17.6%。结论:hme相关的HLH是一种罕见但严重的综合征,死亡率高。早期多用强力霉素治疗是至关重要的,但免疫抑制治疗的作用是个体化的。
{"title":"Ehrlichiosis-Associated Hemophagocytic Lymphohistiocytosis: A Case Series and Review of the Literature.","authors":"Kassem Hammoud,&nbsp;Robert Fulmer,&nbsp;Megan Hamner,&nbsp;Wissam El Atrouni","doi":"10.1155/2023/5521274","DOIUrl":"https://doi.org/10.1155/2023/5521274","url":null,"abstract":"Background Human monocytic ehrlichiosis (HME) is a potentially life-threatening tick-borne illness. HME-associated hemophagocytic lymphohistiocytosis (HLH) is a rare entity with a paucity of published literature regarding treatment and outcome. We present the clinical features, treatment, and outcomes of 4 patients at our institutions with HME-associated HLH. This review also summarizes the current literature regarding the presentation, treatment, and outcome of this infection-related HLH. Methods We searched the PubMed database for case reports and case series. All cases were diagnosed according to the HLH-04 criteria. Results Four cases of HME-associated HLH were included from our institutions. The literature review yielded 30 additional cases. About 41% of the cases were in the pediatric population; 59% were female; and all patients had fever, cytopenia, and elevated ferritin. Most patients were immunocompetent; all but one patient with available data were treated with doxycycline, and eight of the patients with available data received the HLH-94 treatment protocol. The mortality rate was 17.6%. Conclusions HME-associated HLH is a rare but serious syndrome with significant mortality. Early treatment with doxycycline is critical, but the role of immunosuppressive therapy is individualized.","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"5521274"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9358041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient. 一名年轻患者接种mRNA - COVID-19疫苗后快速发生的严重免疫性血小板减少症
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/7877536
Jorge Avila, Huseyin Berk Degirmenci, Pamela Contreras Chavez, Elisabeth M Battinelli, Jorge Fleisher

The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reported in the literature but remain as a rare phenomenon. We present the case of a patient who developed severe thrombocytopenia within twenty-four hours following the Pfizer-BioNTech vaccination. Commonly encountered differentials including heparin-induced thrombocytopenia and common viral etiologies were ruled out, and other causes such as drug reactions deemed unlikely as the etiology of this presentation after a broad workup. Nucleocapsid antibodies against COVID-19 were found to be positive which indicated that vaccination was at least the second encounter with this virus for our patient, which has been reported previously as the cause of immune thrombocytopenia (ITP), and this might be the culprit for sudden onset. He responded to the first-line ITP treatment with corticosteroids and intravenous immunoglobulin (IVIG) as evidenced by the fast recovery of platelet count and lack of recurrence of thrombocytopenia.

2019冠状病毒病(COVID-19)大流行影响了全球数百万人。在美国,针对COVID-19的疫苗接种已被批准用于以下三种疫苗:辉瑞- biontech、Moderna和Janssen。疫苗接种的血液学并发症已在文献中报道,但仍然是一种罕见的现象。我们提出的情况下,患者谁发展严重的血小板减少在二十四小时后,辉瑞biontech疫苗接种。常见的差异包括肝素诱导的血小板减少症和常见的病毒病因被排除,其他原因如药物反应被认为不太可能是广泛检查后的病因。抗COVID-19的核衣壳抗体呈阳性,这表明该患者至少是第二次接种该病毒,这是之前报道的免疫性血小板减少症(ITP)的原因,这可能是突然发病的罪魁祸首。他对皮质类固醇和静脉注射免疫球蛋白(IVIG)的一线ITP治疗有反应,血小板计数恢复迅速,血小板减少症没有复发。
{"title":"Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient.","authors":"Jorge Avila,&nbsp;Huseyin Berk Degirmenci,&nbsp;Pamela Contreras Chavez,&nbsp;Elisabeth M Battinelli,&nbsp;Jorge Fleisher","doi":"10.1155/2023/7877536","DOIUrl":"https://doi.org/10.1155/2023/7877536","url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reported in the literature but remain as a rare phenomenon. We present the case of a patient who developed severe thrombocytopenia within twenty-four hours following the Pfizer-BioNTech vaccination. Commonly encountered differentials including heparin-induced thrombocytopenia and common viral etiologies were ruled out, and other causes such as drug reactions deemed unlikely as the etiology of this presentation after a broad workup. Nucleocapsid antibodies against COVID-19 were found to be positive which indicated that vaccination was at least the second encounter with this virus for our patient, which has been reported previously as the cause of immune thrombocytopenia (ITP), and this might be the culprit for sudden onset. He responded to the first-line ITP treatment with corticosteroids and intravenous immunoglobulin (IVIG) as evidenced by the fast recovery of platelet count and lack of recurrence of thrombocytopenia.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"7877536"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9167005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly. 吉替尼作为老年人FLT3-ITD突变伴髓外疾病的复发性急性髓性白血病的桥接和移植后维持
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/7164742
Masuho Saburi, Masanori Sakata, Rika Maruyama, Yosuke Kodama, Hiroyuki Takata, Yasuhiko Miyazaki, Katsuya Kawano, Junpei Wada, Shogo Urabe, Eiichi Ohtsuka

A 69-year-old woman was diagnosed with acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation. Complete remission (CR) was achieved after induction therapy, but AML resulted in a hematological relapse two months after the consolidation chemotherapy. Relapse was accompanied by multiple skin lesions that demonstrated leukemic cell infiltration as well as a drooping right eyelid with extroversion of the eye due to right oculomotor palsy. Gilteritinib was started as salvage therapy, and bone marrow blasts decreased to 0.8% after one month. Two months later, the eye symptoms improved, and the patient underwent cord blood transplantation (CBT). The skin lesions disappeared after the conditioning regimen, and the patient achieved CR status with complete donor chimerism at day 28. Gilteritinib was restarted as posttransplant maintenance therapy on day 53 of CBT. No adverse events other than mild hepatotoxicity were observed, and the patient was alive and in CR status, while continuing gilteritinib at one year and seven months after CBT. Bridging and posttransplant maintenance therapy with gilteritinib may be a promising therapeutic option for relapsed AML with the FLT3-ITD mutation in elderly patients.

一名69岁的女性被诊断为急性髓性白血病(AML),伴有fms样酪氨酸激酶3-内串联重复(FLT3-ITD)突变。诱导治疗后达到完全缓解(CR),但AML在巩固化疗后两个月导致血液学复发。复发时伴有多发性皮肤病变,表现为白血病细胞浸润,以及右眼运动性麻痹引起的右眼睑下垂和眼外倾。Gilteritinib作为补救性治疗开始,1个月后骨髓原细胞下降至0.8%。两个月后,眼部症状改善,患者接受了脐带血移植(CBT)。调理方案后皮肤病变消失,患者在第28天达到完全供体嵌合的CR状态。在CBT治疗的第53天,Gilteritinib作为移植后维持治疗重新开始。除轻度肝毒性外,未观察到其他不良事件,患者存活并处于CR状态,同时在CBT后1年零7个月继续使用吉特替尼。gilteritinib桥接和移植后维持治疗可能是老年患者FLT3-ITD突变的复发性AML的一种有希望的治疗选择。
{"title":"Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly.","authors":"Masuho Saburi,&nbsp;Masanori Sakata,&nbsp;Rika Maruyama,&nbsp;Yosuke Kodama,&nbsp;Hiroyuki Takata,&nbsp;Yasuhiko Miyazaki,&nbsp;Katsuya Kawano,&nbsp;Junpei Wada,&nbsp;Shogo Urabe,&nbsp;Eiichi Ohtsuka","doi":"10.1155/2023/7164742","DOIUrl":"https://doi.org/10.1155/2023/7164742","url":null,"abstract":"<p><p>A 69-year-old woman was diagnosed with acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation. Complete remission (CR) was achieved after induction therapy, but AML resulted in a hematological relapse two months after the consolidation chemotherapy. Relapse was accompanied by multiple skin lesions that demonstrated leukemic cell infiltration as well as a drooping right eyelid with extroversion of the eye due to right oculomotor palsy. Gilteritinib was started as salvage therapy, and bone marrow blasts decreased to 0.8% after one month. Two months later, the eye symptoms improved, and the patient underwent cord blood transplantation (CBT). The skin lesions disappeared after the conditioning regimen, and the patient achieved CR status with complete donor chimerism at day 28. Gilteritinib was restarted as posttransplant maintenance therapy on day 53 of CBT. No adverse events other than mild hepatotoxicity were observed, and the patient was alive and in CR status, while continuing gilteritinib at one year and seven months after CBT. Bridging and posttransplant maintenance therapy with gilteritinib may be a promising therapeutic option for relapsed AML with the FLT3-ITD mutation in elderly patients.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"7164742"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10154695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidental Diagnosis of Oligosymptomatic Bilateral Perirenal Erdheim-Chester Disease during Emergency Investigation for COVID-19 Infection. COVID-19感染急诊调查中少症状双侧肾周厄德海姆-切斯特病的偶然诊断
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/4683188
Juliano Cordova Vargas, Caio Cardozo, Renata Stanzione, Lucas Fiore, Felipe D'Almeida Costa, Rodrigo Fonseca Abreu, Nelson Hamerschlak, Guilherme Perini

Erdheim-Chester disease (ECD), a rare form of non-Langerhans histiocytosis, is a multisystem disorder. The case reported here refers to a 49-year-old man presenting at the emergency room with respiratory symptoms. While undergoing diagnostic tests for COVID-19 infection, tomography revealed asymptomatic bilateral perirenal tumors, while renal function remained unaltered. ECD was suggested as an incidental diagnosis and confirmed by core needle biopsy. This report provides a brief description of the clinical, laboratory, and imaging findings in this case of ECD. This diagnosis, albeit rare, should be taken into consideration in the context of incidental findings of abdominal tumors to ensure that treatment, when required, is instituted early.

Erdheim-Chester病(ECD)是一种罕见的非朗格汉斯组织细胞增多症,是一种多系统疾病。这里报告的病例是指一名49岁男子在急诊室出现呼吸道症状。在接受COVID-19感染诊断测试时,断层扫描显示无症状的双侧肾周肿瘤,而肾功能保持不变。ECD被认为是偶然诊断,并通过核心针活检证实。本报告简要介绍了本例ECD的临床、实验室和影像学表现。这种诊断虽然罕见,但应考虑到腹部肿瘤的偶然发现,以确保在需要时及早进行治疗。
{"title":"Incidental Diagnosis of Oligosymptomatic Bilateral Perirenal Erdheim-Chester Disease during Emergency Investigation for COVID-19 Infection.","authors":"Juliano Cordova Vargas,&nbsp;Caio Cardozo,&nbsp;Renata Stanzione,&nbsp;Lucas Fiore,&nbsp;Felipe D'Almeida Costa,&nbsp;Rodrigo Fonseca Abreu,&nbsp;Nelson Hamerschlak,&nbsp;Guilherme Perini","doi":"10.1155/2023/4683188","DOIUrl":"https://doi.org/10.1155/2023/4683188","url":null,"abstract":"<p><p>Erdheim-Chester disease (ECD), a rare form of non-Langerhans histiocytosis, is a multisystem disorder. The case reported here refers to a 49-year-old man presenting at the emergency room with respiratory symptoms. While undergoing diagnostic tests for COVID-19 infection, tomography revealed asymptomatic bilateral perirenal tumors, while renal function remained unaltered. ECD was suggested as an incidental diagnosis and confirmed by core needle biopsy. This report provides a brief description of the clinical, laboratory, and imaging findings in this case of ECD. This diagnosis, albeit rare, should be taken into consideration in the context of incidental findings of abdominal tumors to ensure that treatment, when required, is instituted early.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"4683188"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9622727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fat Embolization Syndrome Secondary to Steroid Treatment in a Case of Sickle Cell Vaso-Occlusive Crisis. 脂肪栓塞综合征继发于类固醇治疗镰状细胞血管闭塞危象1例。
IF 0.7 Q4 HEMATOLOGY Pub Date : 2023-01-01 DOI: 10.1155/2023/5530870
Ram Prakash Thirugnanasambandam, Farish Mohamed Maraikayar, Marie Liu, Khalid Elbashir, John Muthu

Fat embolization syndrome (FES) is often seen as a complication of fractures and has been known to cause respiratory failure, rashes of the skin, thrombocytopenia, and neurological damage. Nontraumatic FES is uncommon and occurs due to bone marrow necrosis. Vaso-occlusive crisis in sickle cell patients secondary to steroid therapy is a rare entity and not widely acknowledged. We report a case of FES secondary to steroid therapy administered for a patient with intractable migraine. FES is an uncommon yet serious complication that occurs due to bone marrow necrosis and is usually associated with increased mortality or damaging neurologic sequelae for the surviving patient. Our patient was initially admitted for intractable migraine and worked up to rule out any acute emergency conditions. She was then given steroids for her migraine which did not subside with the initial treatment. Her condition worsened, and she developed respiratory failure along with altered mental status requiring care in the intensive care unit (ICU). Imaging studies showed microhemorrhages throughout the cerebral hemispheres, brainstem, and cerebellum. The imaging of her lungs confirmed severe acute chest syndrome. The patient also had hepatocellular and renal injuries indicative of multiorgan failure. The patient was treated with a red cell exchange transfusion (RBCx) leading to an almost complete recovery in a few days. The patient, however, had residual neurological sequelae with the presence of numb chin syndrome (NCS). This report thus highlights the need to recognize potential multiorgan failure secondary to steroid treatment and the importance of initiating treatment with red cell exchange transfusions to decrease the risk of such complications secondary to steroids.

脂肪栓塞综合征(FES)通常被认为是骨折的并发症,已知会导致呼吸衰竭、皮肤皮疹、血小板减少症和神经损伤。非创伤性FES是罕见的,发生于骨髓坏死。在镰状细胞患者继发于类固醇治疗的血管闭塞危机是一个罕见的实体和不被广泛承认。我们报告一例FES继发于顽固性偏头痛患者的类固醇治疗。FES是一种罕见但严重的并发症,由于骨髓坏死而发生,通常与存活患者死亡率增加或破坏性神经系统后遗症有关。我们的病人最初因难治性偏头痛入院,并排除了任何急性紧急情况。随后,她的偏头痛在最初的治疗中没有得到缓解,医生给了她类固醇。她的病情恶化,并出现呼吸衰竭和精神状态改变,需要在重症监护室(ICU)进行护理。影像学检查显示微出血遍及大脑半球、脑干和小脑。肺部影像学证实她患有严重的急性胸综合征。患者也有肝细胞和肾脏损伤,表明多器官功能衰竭。患者接受了红细胞交换输血(RBCx)治疗,几天后几乎完全康复。然而,患者有残余的神经系统后遗症,存在麻木下巴综合征(NCS)。因此,本报告强调有必要认识到类固醇治疗继发的潜在多器官衰竭,以及开始红细胞交换输注治疗以降低类固醇继发并发症风险的重要性。
{"title":"Fat Embolization Syndrome Secondary to Steroid Treatment in a Case of Sickle Cell Vaso-Occlusive Crisis.","authors":"Ram Prakash Thirugnanasambandam,&nbsp;Farish Mohamed Maraikayar,&nbsp;Marie Liu,&nbsp;Khalid Elbashir,&nbsp;John Muthu","doi":"10.1155/2023/5530870","DOIUrl":"https://doi.org/10.1155/2023/5530870","url":null,"abstract":"<p><p>Fat embolization syndrome (FES) is often seen as a complication of fractures and has been known to cause respiratory failure, rashes of the skin, thrombocytopenia, and neurological damage. Nontraumatic FES is uncommon and occurs due to bone marrow necrosis. Vaso-occlusive crisis in sickle cell patients secondary to steroid therapy is a rare entity and not widely acknowledged. We report a case of FES secondary to steroid therapy administered for a patient with intractable migraine. FES is an uncommon yet serious complication that occurs due to bone marrow necrosis and is usually associated with increased mortality or damaging neurologic sequelae for the surviving patient. Our patient was initially admitted for intractable migraine and worked up to rule out any acute emergency conditions. She was then given steroids for her migraine which did not subside with the initial treatment. Her condition worsened, and she developed respiratory failure along with altered mental status requiring care in the intensive care unit (ICU). Imaging studies showed microhemorrhages throughout the cerebral hemispheres, brainstem, and cerebellum. The imaging of her lungs confirmed severe acute chest syndrome. The patient also had hepatocellular and renal injuries indicative of multiorgan failure. The patient was treated with a red cell exchange transfusion (RBCx) leading to an almost complete recovery in a few days. The patient, however, had residual neurological sequelae with the presence of numb chin syndrome (NCS). This report thus highlights the need to recognize potential multiorgan failure secondary to steroid treatment and the importance of initiating treatment with red cell exchange transfusions to decrease the risk of such complications secondary to steroids.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2023 ","pages":"5530870"},"PeriodicalIF":0.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9815282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Case Reports in Hematology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1